AngioDynamics Reports Fiscal 2013 Second Quarter Financial Results

January 3, 2013 at 4:01 PM EST

  • Pro forma net sales growth of 3% to $87 million
  • Adjusted (Non-GAAP) Net Income of $0.10 per share; GAAP Net Income of $0.06 per share
  • Adjusted EBITDA of $13.8 million; or $0.39 per share, a 26% YOY increase
  • Operating cash flow of $11.1 million

ALBANY, N.Y., Jan. 3, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today reported financial results for the fiscal 2013 second quarter ended November 30, 2012. Financial results include Navilyst Medical operations acquired in May 2012.

Net sales for the second quarter were $87 million, a 50% increase over the $58.1 million reported a year ago. Compared to prior year second quarter pro forma net sales, which include Navilyst Medical and exclude LC Beads sales, total company pro forma net sales increased 3%; U.S. net sales decreased 1%; International net sales increased 21% (22% on a constant currency basis); Vascular net sales increased 1%; and Oncology/Surgery net sales increased 12%. Net sales by product line are presented on a pro forma basis in a table at the end of this news release.

The Company reported second quarter net income of $2 million, or $0.06 per share, compared to net income of $2.3 million, or $0.09 per share, a year ago. Second quarter results include costs related to the Navilyst Medical acquisition, the subsequent restructuring of the Company and the Quality Call to Action Program. Excluding the aforementioned costs, which are set forth in the attached reconciliation table, adjusted (Non-GAAP) net income was $3.6 million, or $0.10 per share, compared to $2.8 million, or $0.11 per share, a year ago. Diluted average shares outstanding increased to 35.3 million in the quarter from 25.3 million in the prior year period due to the additional shares issued in conjunction with the Navilyst Medical acquisition.

Second quarter EBITDA was $11.4 million, or $0.32 per share, compared to $7.1 million, or $0.28 per share, a year ago. Adjusted EBITDA, computed with the adjustments to GAAP reporting set forth in the attached reconciliation table, was $13.8 million, or $0.39 per share, in the second quarter compared to $7.8 million, or $0.31 per share, a year ago.

"We improved our performance in the fiscal second quarter," said Joseph DeVivo, President and CEO. "We met our revenue expectations by generating 3% pro forma growth. Our international, VenaCure EVLT and Oncology/Surgery product offerings all posted double-digit growth. We had strong earnings growth for the quarter and began to demonstrate the type of cash the business can generate by delivering $11.1 million in cash flow from operations and a 26% year-over-year increase in adjusted EBITDA per share. During the quarter, our team significantly increased the value of our portfolio with the addition of the AngioVac device and also began to sell BioFlo PICCs in the U.S. AngioDynamics' financial performance continues to improve, and we are excited about our future growth opportunities."

Operating cash flow improved to $11.1 million compared to $2.7 million in the prior year quarter. At November 30, 2012, cash, escrow receivable and investments were $24 million, and debt was $146.3 million.

Highlights of the reporting and subsequent period include:

  • International pro forma sales growth of 21%, or 22% on a constant currency basis, led by strong sales in Canada, reflecting the establishment of a direct sales operation there, and the sale of Microwave ablation products internationally.
     
  • Oncology/Surgery pro forma sales growth of 12% (excluding LC Beads) led by the sale of Microwave ablation products internationally.
     
  • VenaCure EVLT sales increased 10%, primarily driven by strong worldwide sales of NeverTouch laser fiber kits.
     
  • The Company received U.S. Food and Drug Administration 510(K) clearance for the BioFlo Hybrid PICC featuring BioFlo technology. Designed to reduce the accumulation of catheter-related thrombus on, and in the catheter, this is the second clearance for a vascular access product with BioFlo technology in the U.S. market.
     
  • The acquisition of Vortex Medical Inc., a privately-held company focused on the development of innovative medical devices for venous drainage. The transaction included the AngioVac venous drainage system comprising the AngioVac Cannula and Circuit. These two disposable devices, when combined with other manufacturers' filters, pumps and return cannula, comprise an extracorporeal bypass circuit that facilitates drainage, filtration and reinfusion of blood for up to six hours. The AngioVac Cannula has a proprietary balloon-actuated, expandable, funnel-shaped distal tip that enhances flow, prevents clogging of the cannula and facilitates en bloc removal of undesirable intravascular material. Both the AngioVac Cannula and Circuit are FDA-cleared, and an application has been filed for CE Mark approval.
     
  • The appointment of Mark Frost as Chief Financial Officer (CFO), succeeding retiring CFO Joseph Gersuk, and the appointment of George Bourne to the expanded role of Vice President and Chief Technology & Operations Officer.

For the six months ended November 30, 2012, net sales were $170.4 million, a 51% increase over the $112.5 million reported a year ago and a 1% increase on a pro forma basis. Net income of $1.2 million, or $0.04 per share, compared to $3.7 million, or $0.15 per share, as reported a year ago. Adjusted net income, excluding costs relating to the Navilyst Medical acquisition, as well as other costs detailed in the attached reconciliation, was $7.2 million, or $0.20 per share, compared to $3.7 million, or $0.14 per share, a year ago. Adjusted EBITDA was $27 million, or $0.77 per share, compared to $12.9 million, or $0.51 per share, a year ago.

Fiscal 2013 Guidance  
   
  Adjusted
  Non-GAAP
   
Sales ($ in mils.) (a), (b) 355 — 360
   
Gross Margin (c) 50 - 51%
   
Operating Income ($ in mils.) (d) 29 — 31
   
EBITDA ($ in mils.) (d) (e) 56 — 57
   
EPS ($) (f) 0.40 - 0.42
   
a)  Quarterly calendarization is expected to approximate 23%/24%/25%/28% of the annual amount.
   
b)  Fiscal Year 2012 pro forma combined sales excluding LC Beads were $344.3 million.
   
c)  Excludes $3.4 million for amortization of inventory basis step-up and $1 million for the QCTA/FDA remediation programs, and includes $1.8 million for the medical device tax with effect from January 1, 2013.
   
d)  Adjusted result reflects an estimated $14 million in acquisition-related and restructuring costs, which include amortization of inventory basis step-up, accelerated asset depreciation, transaction-related professional fees, employment severance costs, QCTA/FDA remediation programs, and the closure of the U.K. manufacturing facility. Quarterly calendarization of the $14 million will approximate $7 million/$2 million/$3 million/$2 million.
   
e)  $16 million in amortization, $8 million in depreciation, and $2 million in purchase accounting related to Vortex Medical are excluded from both measures. 
   
(f) Approximately 36 million diluted shares outstanding and a 37% tax rate.

Conference Call

AngioDynamics will host a conference call today at 4:30 p.m. Eastern Time to discuss its second quarter results. To participate in the call, please dial 1-877-941-0844. In addition, a live webcast and archived replay of the call will be available at http://investors.angiodynamics.com. To access the live webcast, please go to the website 15 minutes prior to its start to register, download and install the necessary software.

Use of Non-GAAP Measures

Management uses non-GAAP measures to establish operational goals, and believes that non-GAAP measures may assist investors in analyzing the underlying trends in AngioDynamics' business over time. Investors should consider these non-GAAP measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with GAAP. In this news release, AngioDynamics has reported pro forma sales growth, sales on a constant currency basis, non-GAAP gross margin, non-GAAP operating income, EBITDA (income before interest, taxes, depreciation and amortization), adjusted EBITDA, non-GAAP net income and non-GAAP earnings per share. Management uses these measures in its internal analysis and review of operational performance. Management believes that these measures provide investors with useful information in comparing AngioDynamics' performance over different periods. By using these non-GAAP measures, management believes that investors get a better picture of the performance of AngioDynamics' underlying business. Management encourages investors to review AngioDynamics' financial results prepared in accordance with GAAP to understand AngioDynamics' performance taking into account all relevant factors, including those that may only occur from time to time but have a material impact on AngioDynamics' financial results. Please see the tables that follow for a reconciliation of non-GAAP measures to measures prepared in accordance with GAAP.

About AngioDynamics

AngioDynamics Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. AngioDynamics' diverse product lines include market-leading ablation systems, fluid management systems, vascular access products, angiographic products and accessories, angioplasty products, drainage products, thrombolytic products and venous products. More information is available at www.AngioDynamics.com.

Trademarks

AngioDynamics, the AngioDynamics logo, Navilyst Medical, VenaCure EVLT, NeverTouch, BioFlo and NanoKnife are trademarks and/or registered trademarks of AngioDynamics Inc., an affiliate or a subsidiary.

Safe Harbor

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from AngioDynamics' expectations. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate purchased businesses, including Navilyst Medical and its products, R&D capabilities, infrastructure and employees as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2012. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

         
         
ANGIODYNAMICS, INC. AND SUBSIDIARIES
CONSOLIDATED INCOME STATEMENTS
(in thousands, except per share data)
         
         
  Three months ended Six months ended
  Nov 30,
2012		 Nov 30,
2011		 Nov 30,
2012		 Nov 30,
2011
  (unaudited) (unaudited)
         
Net sales $ 87,007 $ 58,099 $ 170,423 $ 112,530
Cost of sales        
 Acquired inventory step-up  --   --   3,445  -- 
 Quality call to action  113  --   812  -- 
 Other cost of sales  42,806  24,868  82,620  47,154
Total cost of sales   42,919  24,868  86,877  47,154
Gross profit  44,088  33,231  83,546  65,376
% of net sales 50.7% 57.2% 49.0% 58.1%
         
Operating expenses        
 Research and development   7,014  5,125  14,088  10,715
 Sales and marketing  18,671  15,847  37,214  32,156
 General and administrative  6,910  4,625  13,808  8,937
 Amortization of intangibles  4,107  2,300  7,844  4,594
 Acquisition and other non-recurring  2,264  1,408  4,786  2,331
Total operating expenses  38,966  29,305  77,740  58,733
Operating income   5,122  3,926  5,806  6,643
Other income (expense), net  (1,990)  (357)  (3,828)  (971)
Income before income taxes  3,132  3,569  1,978  5,672
Provision for income taxes  1,163  1,240  730  1,970
Net income $ 1,969 $ 2,329 $ 1,248 $ 3,702
         
Earnings per common share      
Basic  $ 0.06  $ 0.09  $ 0.04 $ 0.15
Diluted  $ 0.06  $ 0.09  $ 0.04 $ 0.15
         
Weighted average common shares    
Basic  34,827  25,190  34,765  25,107
Diluted  35,311  25,340  35,279  25,278
         
         
ANGIODYNAMICS, INC. AND SUBSIDIARIES
GAAP TO NON-GAAP RECONCILIATION
(in thousands, except per share data)
         
         
Reconciliation of Net Income to non-GAAP Adjusted Net Income:
         
  Three months ended Six months ended
  Nov 30,
2012		 Nov 30,
2011		 Nov 30,
2012		 Nov 30,
2011
  (unaudited) (unaudited)
         
Net income $ 1,969 $ 2,329 $ 1,248 $ 3,702
         
After tax:        
Acquisition and other non-recurring (1)  1,539  907  3,149  1,500
Quality Call to Action Program (2)  73  --   528  -- 
Inventory step-up (3)  --   --   2,239  -- 
Product recalls (4)  --   924  --   924
LC Beads contribution (5)  --   (1,392)  --   (2,468)
Adjusted net income  $ 3,581  $ 2,768  $ 7,164  $ 3,658
         
         
Reconciliation of Diluted Earnings Per Share to non-GAAP Adjusted Diluted Earnings Per Share:
         
  Three months ended Six months ended
  Nov 30,
2012		 Nov 30,
2011		 Nov 30,
2012		 Nov 30,
2011
  (unaudited) (unaudited)
         
Diluted earnings per share $ 0.06 $ 0.09 $ 0.04  $ 0.15
         
After tax:        
Acquisition and other non-recurring (1)  0.04  0.04  0.09  0.06
Quality Call to Action Program (2)  0.00  --   0.01  -- 
Inventory step-up (3)  --   --   0.06  -- 
Product recalls (4)  --   0.04  --   0.04
LC Beads contribution (5)  --   (0.05)  --   (0.10)
Adjusted diluted earnings per share  $ 0.10  $ 0.11  $ 0.20  $ 0.14
         
* Does not sum due to rounding        
         
(1) Includes costs relating to acquisitions, debt financing, business restructuring and executive transitions, and a program to close a manufacturing facility in the U.K.
(2) Direct costs of implementing a comprehensive Quality Call to Action program to review and augment the quality management systems at our Queensbury and Fremont facilities.
(3) Amortization of basis step-up of acquired Navilyst inventory.
(4) Costs attributable to voluntary product recalls.
(5) Reflects estimated contribution of LC Beads distribution contract which expired on December 31, 2011.
         
         
ANGIODYNAMICS, INC. AND SUBSIDIARIES
GAAP TO NON-GAAP RECONCILIATION (Continued)
(in thousands, except per share data)
         
         
Reconciliation of Net Income to EBITDA and Adjusted EBITDA:
         
  Three months ended Six months ended
  Nov 30,
2012		 Nov 30,
2011		 Nov 30,
2012		 Nov 30,
2011
  (unaudited) (unaudited)
         
Net income $ 1,969 $ 2,329 $ 1,248 $ 3,702
         
Provision for income taxes  1,163  1,240  730  1,970
Other income (expense), net  1,990  357  3,828  971
Amortization of intangibles  4,107  2,300  7,844  4,594
Depreciation  2,185  841  4,317  1,679
EBITDA  11,414  7,067  17,967  12,916
         
Acquisition and other non-recurring (1)  2,264  1,408  4,786  2,331
Quality Call to Action Program (2)  113  --   812  -- 
Inventory step-up (3)  --   --   3,445  -- 
Product recalls (4)  --   1,422  --   1,422
LC Beads contribution (5)  --   (2,141)    (3,797)
Adjusted EBITDA  $ 13,791  $ 7,756  $ 27,010  $ 12,872
         
EBITDA per common share        
Assumes Diluted  $ 0.32 $ 0.28 $ 0.51 $ 0.51
         
Adjusted EBITDA per common share        
Assumes Diluted $ 0.39 $ 0.31 $ 0.77 $ 0.51
         
         
Reconciliation of Operating Income to non-GAAP Adjusted Operating Income:  
         
  Three months ended Six months ended
  Nov 30,
2012		 Nov 30,
2011		 Nov 30,
2012		 Nov 30,
2011
  (unaudited) (unaudited)
         
Operating income  $ 5,122 $ 3,926 $ 5,806 $ 6,643
         
Acquisition and other non-recurring (1)  2,264  1,408  4,786  2,331
Quality Call to Action Program (2)  113  --   812  -- 
Inventory step-up (3)  --   --   3,445  -- 
Product recalls (4)  --   1,422  --   1,422
LC Beads contribution (5)  --   (2,141)    (3,797)
Adjusted Operating income  $ 7,499  $ 4,615  $ 14,849  $ 6,599
         
         
(1) Includes costs relating to acquisitions, debt financing, business restructuring and executive transitions, and a program to close a manufacturing facility in the U.K.
(2) Direct costs of implementing a comprehensive Quality Call to Action program to review and augment the quality management systems at our Queensbury and Fremont facilities.
(3) Amortization of basis step-up of acquired Navilyst inventory.
(4) Costs attributable to voluntary product recalls.
(5) Reflects estimated contribution of LC Beads distribution contract which expired on December 31, 2011.
             
             
ANGIODYNAMICS, INC. AND SUBSIDIARIES
CONSOLIDATED INCOME STATEMENT NON GAAP RECONCILIATION
FOR THE QUARTER ENDED NOVEMBER 30, 2012
(in thousands, except per share data)
(Unaudited)
             
             
    Quality Acquisition Severance/    
  GAAP Control Related Restructuring Other NON GAAP
  Results Initiative Costs Costs Items, Net Results
             
             
Net sales $ 87,007         $ 87,007
Cost of sales   42,919  (113)        42,806
Gross profit  44,088  113  --   --   --   44,201
% of net sales 50.7%         50.8%
             
Operating expenses            
 Research and development   7,014          7,014
 Sales and marketing  18,671          18,671
 General and administrative  6,910          6,910
 Amortization of intangibles  4,107          4,107
 Acquisition and other non-recurring  2,264    (1,094)  (1,330)  160  -- 
Total operating expenses  38,966  --   (1,094)  (1,330)  160  36,702
Operating income   5,122  113  1,094  1,330  (160)  7,499
Other income (expense), net  (1,990)          (1,990)
Income before income taxes  3,132  113  1,094  1,330  (160)  5,509
Provision for income taxes  1,163  40  315  466  (56)  1,928
Net income $ 1,969 $ 73 $ 779 $ 864  $ (104) $ 3,581
             
Earnings per common share            
Assumes Diluted  $ 0.06  $ 0.00  $ 0.02  $ 0.02  $ (0.00)  $ 0.10
             
Weighted average common shares            
Assumes Diluted  35,311  35,311  35,311  35,311  35,311  35,311
             
Effective Tax Rate 37% 35% 29% 35% 35% 35%
             
             
ANGIODYNAMICS, INC. AND SUBSIDIARIES
CONSOLIDATED INCOME STATEMENT NON GAAP RECONCILIATION
FOR THE SIX MONTHS ENDED NOVEMBER 31, 2012
(in thousands, except per share data)
(Unaudited)
             
             
    Quality Acquisition Severance/    
  GAAP Control Related Restructuring Other NON GAAP
  Results Initiative Costs Costs Items, Net Results
             
             
Net sales $ 170,423         $ 170,423
Cost of sales   86,877  (812)  (3,445)      82,620
Gross profit  83,546  812  3,445  --   --   87,803
% of net sales 49.0%         51.5%
             
Operating expenses            
 Research and development   14,088          14,088
 Sales and marketing  37,214          37,214
 General and administrative  13,808          13,808
 Amortization of intangibles  7,844          7,844
 Acquisition and other non-recurring  4,786    (1,996)  (2,818)  28  -- 
Total operating expenses  77,740  --   (1,996)  (2,818)  28  72,954
Operating income   5,806  812  5,441  2,818  (28)  14,849
Other income (expense), net  (3,828)          (3,828)
Income before income taxes  1,978  812  5,441  2,818  (28)  11,021
Provision for income taxes  730  285  1,866  986  (10)  3,857
Net income $ 1,248 $ 527 $ 3,575 $ 1,832  $ (18) $ 7,164
             
Earnings per common share            
Assumes Diluted  $ 0.04  $ 0.01  $ 0.10  $ 0.05  $ (0.00)  $ 0.20
             
Weighted average common shares            
Assumes Diluted  35,279  35,279  35,279  35,279  35,279  35,279
             
Effective Tax Rate 37% 35% 34% 35% 35% 35%
             
             
ANGIODYNAMICS, INC. AND SUBSIDIARIES
NET SALES BY PRODUCT CATEGORY AND BY GEOGRAPHY
(unaudited in thousands)
             
             
  Three months ended Six months ended
  Nov 30,
2012		 Nov 30,
2011		 %
Growth		 Nov 30,
2012		 Nov 30,
2011		 %
Growth
AS REPORTED            
             
Net Sales by Product Category            
Vascular            
Peripheral Vascular $ 45,766 $ 23,079 98% $ 89,061 $ 44,047 102%
Vascular Access  26,712  15,203 76%  53,341  30,800 73%
Total Vascular  72,478  38,282 89%  142,402  74,847 90%
Oncology/Surgery  12,006  19,817 (39%)  23,239  37,683 (38%)
Supply Agreement  2,523  -- N/A  4,782  -- N/A
Total $ 87,007 $ 58,099 50% $ 170,423 $ 112,530 51%
             
Net Sales by Geography            
United States $ 69,652 $ 49,653 40% $ 137,680 $ 96,958 42%
International  17,355  8,446 105%  32,743  15,572 110%
Total $ 87,007 $ 58,099 50% $ 170,423 $ 112,530 51%
             
PRO FORMA (a)            
             
Net Sales by Product Category            
Vascular            
Peripheral Vascular $ 45,766 $ 44,393 3% $ 89,061 $ 87,513 2%
Vascular Access  26,712  27,428 (3%)  53,341  55,708 (4%)
Total Vascular  72,478  71,821 1%  142,402  143,221 (1%)
Oncology/Surgery  12,006  10,722 12%  23,239  20,559 13%
Supply Agreement  2,523  2,221 14%  4,782  5,199 (8%)
Total $ 87,007 $ 84,764 3% $ 170,423 $ 168,979 1%
             
Net Sales by Geography            
United States $ 69,652 $ 70,408 (1%) $ 137,680 $ 141,182 (2%)
International  17,355  14,356 21%  32,743  27,797 18%
Total $ 87,007 $ 84,764 3% $ 170,423 $ 168,979 1%
             
(a) As if AngioDynamics (excluding LC Beads) and Navilyst Medical were combined in all periods.
             
             
ANGIODYNAMICS, INC. AND SUBSIDIARIES
PRO FORMA PRODUCT LINE NET SALES EXCLUDING LC BEADS
(in thousands)
             
             
  Three months ended Six months ended
  Nov 30,
2012		 Nov 30,
2011		 %
Growth		 Nov 30,
2012		 Nov 30,
2011		 %
Growth
  (unaudited)   (unaudited)  
Net Sales by Product Line            
Vascular            
Peripheral Vascular            
Fluid Management $ 20,091 $ 20,587 (2%) $ 41,206 $ 41,505 (1%)
Venacure EVLT  11,599  10,555 10%  20,239  18,884 7%
Core products  13,400  13,324 1%  26,729  26,642 0%
Other  676  (73) N/A  887  482 84%
Total Peripheral Vascular  45,766  44,393 3%  89,061  87,513 2%
             
Vascular Access            
PICCS  13,023  13,533 (4%)  25,905  27,100 (4%)
Ports  7,825  7,969 (2%)  15,509  15,655 (1%)
Dialysis  4,753  5,128 (7%)  9,381  10,709 (12%)
Other  1,111  798 39%  2,546  2,244 13%
Total Vascular Access  26,712  27,428 (3%)  53,341  55,708 (4%)
Total Vascular  72,478  71,821 1%  142,402  143,221 (1%)
Oncology/Surgery            
Thermal Ablation  6,880  5,787 19%  13,501  11,585 17%
Nanoknife  3,227  3,215 0%  6,171  5,466 13%
Other  1,899  1,720 10%  3,567  3,508 2%
Total Oncology/Surgery  12,006  10,722 12%  23,239  20,559 13%
Supply Agreement  2,523  2,221 14%  4,782  5,199 (8%)
Total Net Sales $ 87,007 $ 84,764 3% $ 170,423 $ 168,979 1%
             
             
Net Sales by Geography            
United States $ 69,652 $ 70,408 (1%) $ 137,680 $ 141,182 (2%)
International  17,355  14,356 21%  32,743  27,797 18%
Total $ 87,007 $ 84,764 3% $ 170,423 $ 168,979 1%
     
     
ANGIODYNAMICS, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(in thousands)
     
     
  Nov 30,
2012		 May 31,
2012
  (unaudited) (unaudited)
Assets    
Current Assets    
Cash and cash equivalents $ 19,322 $ 23,508
Escrow receivable  2,500  2,500
Marketable securities  2,155  14,070
 Total cash, escrow receivable and investments  23,977  40,078
     
Receivables, net  47,085  48,588
Inventories, net  62,330  55,823
Deferred income taxes  6,728  4,923
Prepaid income taxes  2,449  3,180
Prepaid expenses and other  8,894  6,646
 Total current assets  151,463  159,238
     
Property, plant and equipment, net  58,547  55,915
Intangible assets, net  212,303  147,266
Goodwill  337,190  308,912
Deferred income taxes  9,278  39,198
Other non-current assets  10,166  11,240
 Total Assets $ 778,947 $ 721,769
     
Liabilities and Stockholders' Equity    
Current portion of long-term debt $ 7,500 $ 7,500
Current portion of contingent consideration  8,055  --
Other current liabilities  44,830  47,922
 Total current liabilities  60,385  55,422
Long-term debt, net of current portion  138,750  142,500
Contingent consideration, net of current portion  52,444  --
Other long-term liabilities  680  327
 Total Liabilities  252,259  198,249
     
Stockholders' equity  526,688  523,520
 Total Liabilities and Stockholders' Equity $ 778,947 $ 721,769
     
Shares outstanding  34,974  34,827
         
         
ANGIODYNAMICS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
         
         
  Three months ended Six months ended
  Nov 30,
2012		 Nov 30,
2011		 Nov 30,
2012		 Nov 30,
2011
  (unaudited) (unaudited) (unaudited) (unaudited)
         
Cash flows from operating activities:        
 Net income   $ 1,969  $ 2,329  $ 1,248 $ 3,702
 Depreciation and amortization   6,292  3,141  12,161  6,273
 Tax effect of exercise of stock options   (504)  42  (504)  (198)
 Deferred income taxes   2,260  147  2,175  1,058
 Stock-based compensation   1,252  1,078  2,375  1,877
 Amortization of inventory step-up   --   --   3,445  -- 
 Other   (378)  712  (368)  168
 Changes in operating assets and liabilities         
 Receivables   (1,698)  (5,237)  1,497  (4,515)
 Inventories   1,084  (207)  (9,952)  (1,546)
 Accounts payable and accrued liabilities   (48)  2,509  (6,861)  892
 Other   901  (1,845)  299  (1,998)
 Net cash provided by operating activities   11,130  2,669  5,515  5,713
         
 Cash flows from investing activities:         
 Additions to property, plant and equipment   (3,819)  (517)  (4,787)  (1,058)
 Acquisition of businesses, net of cash acquired   (15,166)  (300)  (14,308)  (300)
 Proceeds from sale of assets   801  --   801  1,000
 Purchases, sales and maturities of marketable securities, net   9,452  (7,634)  11,855  (8,377)
 Net cash used in investing activities   (8,732)  (8,451)  (6,439)  (8,735)
         
Cash flows from financing activities:        
 Repayment of long-term debt   (1,875)  (70)  (3,750)  (135)
 Proceeds from exercise of stock options and ESPP   (103)  446  476  2,250
 Repurchase and retirement of shares   --   (2,104)  --   (2,104)
 Net cash (used in) provided by financing activities   (1,978)  (1,728)  (3,274)  11
         
 Effect of exchange rate changes on cash   6  (28)  12  (18)
 Increase (Decrease) in cash and cash equivalents   426  (7,538)  (4,186)  (3,029)
         
Cash and cash equivalents        
 Beginning of period   18,896  50,493  23,508  45,984
 End of period  $ 19,322 $ 42,955 $ 19,322 $ 42,955 
CONTACT: Company Contact:

         AngioDynamics, Inc.Mark Frost, CFO

         (800) 772-6446 x1981

         mfrost@AngioDynamics.com



         Investor Relations Contacts:

         EVC Group, Inc.Jamar Ismail/Robert Jones

         (415) 568-9348; (646) 201-5447

         jismail@evcgroup.com; bjones@evcgroup.com



         Media Contact:

         EVC Group, Inc.Chris Gale

         (646) 201-5431

         cgale@evcgroup.com
Source: AngioDynamics

News Provided by Acquire Media